Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

Adipose-Derived Stem Cell Products and Combination Therapies for the Treatment of Pathological Scars: A Review of Current Preclinical and Clinical Studies.

Alfarafisa NM., Chou Y., Santika R., Riestiano BE., Soedjana H., Syamsunarno MRAA.

Clinical Trial with a reported sample of 43 on Scar, published in Clin Cosmet Investig Dermatol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Clin Cosmet Investig Dermatol (2025)
Country
New Zealand
Reported sample size
43
Source database
PubMed
PMID
40452780
PMCID
PMC12126117
DOI
10.2147/CCID.S511067
Citations
2

Abstract (original English)

Introduction Pathological scars, including hypertrophic, keloid, and atrophic scars, remain challenging to treat, with current therapies offering limited success. Adipose-derived stem cell (ADSC) products, classified into cell-based therapies (stromal vascular fraction [SVF], ADSCs) and cell-free therapies (adipose tissue extract [ATE], secretomes, exosomes, extracellular vesicles), have emerged as potential treatments. Purpose This review examines the therapeutic potential of ADSC products for pathological scars in preclinical and clinical trials, aiming to bridge the gap between experimental research and clinical application. The effectiveness of ADSC products as monotherapies and in combination with other treatments has also been explored. Methods A comprehensive literature search followed the PICO framework, utilizing electronic databases such as PubMed and Scopus. Original research articles, including both preclinical and clinical trials, were included. Results This review included 43 studies that demonstrated the potential of ADSC products to improve pathological scars. ADSC products improve scar texture by regulating ECM, promoting adipogenesis and angiogenesis, and reducing inflammation in hypertrophic and keloid scars. In addition, ADSC products also prevented collagen degradation in atrophic scars. Although their effectiveness varied, ADSC products also showed potenti

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research